For those that missed it in the H1, probably the most pertinent part:
'...Strong news flow will continue in 2017 as we report on the clinical progress of CAVATAK as a potential new treatment in the fast-growing field of cancer immunotherapy.'
Bring it on...
Good buying opportunity atm, in my opinion...
ML
Add to My Watchlist
What is My Watchlist?